EW
The heart valve business is still pumping
Edwards Lifesciences opened the quarter with a pretty clean message: business is still growing, and not in the sleepy, beige kind of way. For Q2 2026, sales climbed 13.6% to $1.74 billion, while constant-currency sales rose 12.5%. That’s the kind of number that tells you demand is still doing its thing even after you strip out currency noise.
TAVR is doing the heavy lifting
The real engine here was TAVR, Edwards’ flagship transcatheter aortic valve replacement franchise. Q2 TAVR sales rose 11.3% to $1.26 billion, which is a nice reminder that the company’s core growth story is still very much alive. Meanwhile, TMTT sales hit $195.9 million, helped along by its repair and replacement therapies.
Why investors should care
This is the classic “nothing broke” earnings report — and in biotech-ish medtech, that can be a huge win. Investors want to see:
- core products still growing
- newer platforms scaling instead of sulking
- clinical momentum backing up the commercial story
Edwards also pointed to recent clinical data at New York Valves as reinforcing its best-in-class positioning. Translation: the company is trying to keep both the sales pitch and the science pitch in sync, which is usually how you keep the market from getting twitchy.
Big picture: Edwards didn’t just report a quarter; it basically said the valve trade is still in good shape. And for shareholders, that’s a lot better than a dramatic plot twist.